Innovative Research. Personalized Options. Hope for Tomorrow.
At the UMC TLC² Foundation Cancer Center, we believe research is care. Through TTUHSC’s leadership in research and clinical trials, our adult and pediatric studies offer access to new therapies, advanced technologies, and groundbreaking approaches that may not be available elsewhere in the region.
Together with world-class TTUHSC researchers and leading pharmaceutical innovators, we bring cutting-edge science directly to West Texas and Eastern New Mexico. Here, patients can stay close to home while receiving world-class cancer care.
Adult Clinical Trials
Our adult clinical trials program is dedicated to advancing cancer care by improving detection, treatment, and quality of life for patients with a wide range of cancers. This research includes specific cancers such as breast, genitourinary (prostate, kidney), and lung cancers.
Study Title: NRG-BR007: A PHASE III CLINICAL TRIAL EVALUATING DE-ESCALATION OF BREAST RADIATION FOR CONSERVATIVE TREATMENT OF STAGE I, HORMONE SENSITIVE, HER2-NEGATIVE, ONCOTYPE RECURRENCE SCORE ≤ 18 BREAST CANCER (DEBRA)
Short Summary of Study: The purpose of the study is to evaluate whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Clinicaltrials.gov ID: NCT04852887
Study Title: NRG-BR009: A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)
Short Summary of Study: This study is to determine whether post-surgery chemotherapy added to ovarian function suppression plus endocrine therapy is superior to JUST ovarian function suppression plus endocrine therapy in improving invasive breast cancer-free survival among premenopausal, early-stage breast cancer patients with ER positive and HER 2 Negative tumors.
Clinicaltrials.gov ID: NCT05879926
Study Title: S1931: Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)
Short Summary of Study: This phase III trial compares the effect of adding surgery to a standard of care immunotherapy-based drug combination versus a standard of care immunotherapy-based drug combination alone in treating patients with metastatic kidney cancer.
Clinicaltrials.gov ID: NCT04510597
Study Title: S2312: A Phase III Study of Cabazitaxel With or Without Carboplatin in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC), Stratified by Aggressive Variant Signature
Short Summary of Study: This phase III trial compares the effect of adding carboplatin to the standard of care chemotherapy drug cabazitaxel versus cabazitaxel alone in treating metastatic castrate resistant prostate cancer.
Clinicaltrials.gov ID: NCT06470243
Study Title: A Phase Ib, Open-Label, Safety, Tolerability, and Efficacy Study of HC-7366 in Combination with Belzutifan (WELIREG™) in Subjects with Locally Advanced or Metastatic Renal Cell Carcinoma
Short Summary of Study: The primary purpose of this study is to determine the maximum tolerated dose of HC-7366 in combination with belzutifan in patients with locally advanced (inoperable) or metastatic RCC with predominantly clear cell histology, irrespective of VHL gene mutation status.
Clinicaltrials.gov ID: NCT06234605
Pediatric Clinical Trials
We offer a robust portfolio of trials for children, adolescents, and young adults with cancer. Our pediatric trials span leukemia, brain tumors, genitourinary cancers, sarcomas, neuroblastoma, Hodgkin lymphoma, and more.
Study Title: AALL1621: A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518, IND#133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
Short Summary of Study: This phase II trial studies how well inotuzumab ozogamicin works in treating younger patients with B-lymphoblastic lymphoma (B-ALL) or CD22 positive B-ALL that has come back or does not respond to treatment.
Clinicaltrials.gov ID: NCT02981628
Study Title: AALL1732: A Phase III Trial of Inotuzumab Ozogamicin (IND#133494, NSC #772518) for Newly Diagnosed High-Risk B-ALL: Risk-Adapted Post-Induction Therapy for High-Risk -ALL, Mixed Phenotype Acute Leukemia and Disseminated B-LLy
Short Summary of Study: This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. Note: At the current time, this study is only open for MPAL and B-LLy diagnoses.
Clinicaltrials.gov ID: NCT03959085
Study Title: AALL1821: A Phase II Study of Blinatumomab (NSC# 765986, IND# 147294) in Combination with Nivolumab (NSC# 748726, IND# 147294), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse
Short Summary of Study: This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back. Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient’s immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.
Clinicaltrials.gov ID: NCT04546399
Study Title: AALL2131: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
Short Summary of Study: This pilot trial assesses the effect of the combination of blinatumomab with dasatinib or imatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (Ph+) or ABL-class Philadelphia chromosome-like (Ph-like) B-Cell acute lymphoblastic leukemia (B-ALL). Giving blinatumomab and dasatinib or imatinib in combination with standard chemotherapy may work better in treating patients with Ph+ or Ph-like ABL-class B-ALL than dasatinib or imatinib with chemotherapy.
Clinicaltrials.gov ID: NCT06124157
Study Title: APAL2020SC: Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias
Short Summary of Study: This study aims to use clinical and biological characteristics of acute leukemias to screen for patient eligibility for available pediatric leukemia sub-trials. Testing bone marrow and blood from patients with leukemia that has come back after treatment or is difficult to treat may provide information about the patient’s leukemia that is important when deciding how to best treat it, and may help doctors find better ways to diagnose and treat leukemia in children, adolescents, and young adults.
Clinicaltrials.gov ID: NCT04726241
Study Title: ACCL1931: A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
Short Summary of Study: This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Clinicaltrials.gov ID: NCT05602194
Study Title: ACNS1833: A Phase III Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Short Summary of Study: This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.
Clinicaltrials.gov ID: NCT04166409
Study Title: PEPN2415: A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD1390 (NSC# 852149, IND# 172675) When Combined with Focal Radiation in Pediatric Patients with High Grade Glioma
Short Summary of Study: This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. Giving AZD1390 with radiation may be safe, tolerable, and/or effective in treating pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma.
Clinicaltrials.gov ID: NCT06894979
Study Title: AGCT1531: A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors
Short Summary of Study: This phase III trial studies how well active surveillance help doctors to monitor patients with low-risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Clinicaltrials.gov ID: NCT03067181
Study Title: AGCT1532: A Randomized Phase III Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Metastatic Germ Cell Tumors (P3BEP)
Short Summary of Study: The purpose of this study is to determine whether accelerated Bleomycin, Etoposide and Cisplatin (BEP) chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumors.
Clinicaltrials.gov ID: NCT02582697
Study Title: AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Short Summary of Study: This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial Wilms tumor).
Clinicaltrials.gov ID: NCT04322319
Study Title: AREN2231: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
Short Summary of Study: This phase III trial studies using risk factors in determining treatment for children with favorable histology Wilms tumors (FHWT). Wilms tumor is the most common type of kidney cancer in children, and FHWT is the most common subtype. Previous large clinical trials have established treatment plans that are likely to cure most children with FHWT, however some children still have their cancer come back (called relapse) and not all survive. Previous research has identified features of FHWT that are associated with higher or lower risks of relapse. The term “risk” refers to the chance of the cancer coming back after treatment. Using results of tumor histology tests, biology tests, and response to therapy may be able to improve treatment for children with FHWT.
Clinicaltrials.gov ID: NCT06401330
Study Title: AHOD2131: A Randomized Phase III Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
Short Summary of Study: This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone.
Clinicaltrials.gov ID: NCT05675410
Study Title: ANBL2131: A Phase III Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
Short Summary of Study: This phase III trial tests how well the addition of dinutuximab to induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy works for treating children with newly diagnosed high-risk neuroblastoma. When chemotherapy and immunotherapy are given together, during the same treatment cycle, it is called chemoimmunotherapy. This clinical trial randomly assigns patients to receive either standard chemotherapy and surgery or chemoimmunotherapy (chemotherapy plus dinutuximab) and surgery during induction therapy. Chemotherapy drugs given during induction include, cyclophosphamide, topotecan, cisplatin, etoposide, vincristine, and doxorubicin. These drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing or by stopping them from spreading. Upon completion of five cycles of induction therapy, a disease evaluation is completed to determine how well the treatment worked. If the tumor responds to therapy, patients receive a tandem transplantation with stem cell rescue. If the tumor has little improvement or worsens, patients receive chemoimmunotherapy on extended induction. During extended induction, dinutuximab is given with irinotecan, temozolomide. Patients with a good response to therapy move on to Consolidation therapy, when very high doses of chemotherapy are given at two separate points to kill any remaining cancer cells. Following transplant, radiation therapy is given to the site where the cancer originated (primary site) and to any other areas that are still active at the end of induction. The final stage of therapy is post-consolidation. During post-consolidation, dinutuximab is given with isotretinoin, with the goal of maintaining the response achieved with the previous therapy. Adding dinutuximab to induction chemotherapy along with standard of care surgical resection of the primary tumor, radiation, stem cell transplantation, and immunotherapy may be better at treating children with newly diagnosed high-risk neuroblastoma.
Clinicaltrials.gov ID: NCT06172296
Study Title: AOST2032: A Feasibility and Randomized Phase II/III Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Short Summary of Study: This phase II/III trial tests the safety, side effects, and best dose of the drug cabozantinib in combination with standard chemotherapy, and to compare the effect of adding cabozantinib to standard chemotherapy alone in treating patients with newly diagnosed osteosarcoma. Adding cabozantinib to standard chemotherapy may work better in treating newly diagnosed osteosarcoma.
Clinicaltrials.gov ID: NCT05691478
Study Title: ARST2032: A Prospective Phase III Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Short Summary of Study: Rhabdomyosarcoma is a type of cancer that occurs in the soft tissues in the body. This phase III trial aims to maintain excellent outcomes in patients with very low risk rhabdomyosarcoma (VLR-RMS) while decreasing the burden of therapy using treatment with 24 weeks of vincristine and dactinomycin (VA) and examines the use of centralized molecular risk stratification in the treatment of rhabdomyosarcoma. Another aim of the study it to find out how well patients with low-risk rhabdomyosarcoma (LR-RMS) respond to standard chemotherapy when patients with VLR-RMS and patients who have rhabdomyosarcoma with DNA mutations get separate treatment. Finally, this study examines the effect of therapy intensification in patients who have RMS cancer with DNA mutations to see if their outcomes can be improved.
Clinicaltrials.gov ID: NCT05304585
Study Title: APEC14B1: The Project Every Child Protocol: A Registry Eligibility Screening, Biology and Outcome Study
Short Summary of Study: This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.
Clinicaltrials.gov ID: NCT02402244
Study Title: ACCESS Study: Case Ascertainment for Epidemiologic Studies of Childhood Cancers and Hematological Conditions – Adolescent and Childhood Cancer Epidemiology and Susceptibility Service (ACCESS) for Texas
Short Summary of Study: The Epidemiology Center at Texas Children’s Cancer and Hematology Centers/Baylor College of Medicine, currently collects biological specimens and questionnaire data on cases of childhood cancer, hematological conditions, and PCS that are treated in the Texas Children’s Cancer and Hematology Centers and their parents, as well as information and specimens from population-based control subjects in the Houston area. Even with this comprehensive approach, it will take years to accrue enough participants to make meaningful observations with regard to the causes of childhood cancer. They are partnering with other institutions to gather additional cases of childhood cancer, hematological conditions, and PCS for these studies. This collaborative effort will enable Texas Children’s Cancer and Hematology Centers/Baylor College of Medicine to more quickly perform epidemiologic (case-control and triad) studies to explore new risk factors by comparing epidemiologic and genetic characteristics between pediatric cancer and healthy controls (case-control studies) or by comparing the transmission rates of risk genes among pediatric cancer patients and their parents (triad studies).
Clinicaltrials.gov ID: None ACCESS is described as a “Service,” not a clinical trial
Why Participate in a Clinical Trial?
Access to Tomorrow’s Treatments, Today
Gain access to promising new therapies and advanced technologies that are not yet widely available.
Expert, Personalized Care
Receive care from a team of oncologists, researchers, and specialized nurses dedicated to your well-being. Many trials are designed to target specific tumor types, different stages of cancer, and genetic markers, offering a highly personalized approach to your treatment.
Personalized Approach
Many trials target specific tumor types, stages, or genetic markers.
Empower Others, Contribute to the Future
By participating, you play an essential role in a community of hope, helping to advance cancer care and bring us closer to a future without this disease.
Participation in a trial is always voluntary, and you can discuss all potential risks and benefits with your care team before enrolling.
Questions to Ask Before Joining a Clinical Trial
Deciding to participate in a clinical trial is an important and personal choice. Before enrolling, it’s helpful to have a clear understanding of what to expect. Here are some questions you may want to ask your doctor, nurse, or research coordinator:
Tip: Bring a family member or friend to your appointment to help take notes and ask additional questions you may not think of in the moment.
About the Trial
- What is the purpose of this study?
- How does this trial differ from the standard treatment for my type of cancer?
- Has this treatment been tested before, and what were the results?
Eligibility & Enrollment
- How do I know if I’m eligible for this trial?
- What tests or procedures are needed before I can join?
- Can I still receive care from my current doctor while participating?
Risks & Benefits
- What are the potential benefits for me?
- What are the known risks or side effects?
- Are there any long-term effects to consider?
Treatment & Care
- How will the treatment be given and for how long?
- Where will I need to go for treatment?
- Who will be in charge of my care during the trial?
- Will I need to be hospitalized?
Time & Lifestyle
- How often will I have appointments, tests, or hospital visits?
- Will the trial require me to travel or stay overnight?
- How might participation affect my daily life or ability to work?
Costs & Insurance
- Will my insurance cover the cost of the standard care portions of the trial?
- What costs are covered by the trial sponsor?
- Will I be responsible for any out-of-pocket expenses?
After the Trial
- What happens if the trial treatment is working well for me—can I continue it after the study ends?
- Will I be informed of the trial’s results?
- What follow-up care will I need after the trial?
Ask your oncologist whether a clinical trial might be right for you. Take an active step toward advancing cancer care.
Contact Us About Clinical Trials
806.775.8600
clinicalresearch@ttuhsc.edu